Zealand Pharma’s presentation at the J.P. Morgan 31st Annual Healthcare Conference to be live audio webcast
1/4/2013 7:36 AM EST
Zealand Pharma A/S
Investor News
Zealand Pharma’s presentation at the J.P. Morgan 31st Annual Healthcare
Conference to be live audio webcast
Copenhagen, Denmark, 2013-01-04 13:36 CET (GLOBE NEWSWIRE) -- Zealand Pharma
(NASDAQ OMX Copenhagen: ZEAL) informs that the company’s presentation at the JP
Morgan 31st Annual Healthcare Conference in San Francisco on 10 January 2013
will be live audio webcast. The presentation is scheduled to begin at 14:00 PST
(23:00 CET) and will be given by Dr. David Solomon, President and CEO of
Zealand Pharma.
The presentation will include an overview of the company and its main pipeline
activities, including an update on lixisenatide (Lyxumia®), a GLP-1 agonist
invented by Zealand Pharma and licensed to Sanofi for the treatment of Type 2
diabetes. Lixisenatide is currently under regulatory review in a large number
of countries globally, and in November 2012, the European Committee for Human
Medicinal Products issued a positive recommendation for approval of the product
in Europe.
No new financial or other material new information relating to Zealand Pharma
will be disclosed at the event.
The webcast will be available via the following link
http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=ZLDPF,
which can also be accessed from the Investor Section of Zealand Pharma’s
website (www.zealandpharma.com). Participants are advised to register for the
webcast approximately 10 minutes before the start.
An on-demand replay version of the webcast will also be available on the
company’s website following the presentation.
# # #
For further information, please contact:
Zealand Pharma A/S
Hanne Leth Hillman, Vice President for IR & Corporate Communication,
Tel: +45 50 60 36 89, email:
About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company
based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company’s focus lies in the field of diabetes/metabolic
diseases, and its lead drug invention is lixisenatide (Lyxumia® 1), a
once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type
2 diabetes. Lixisenatide is currently under regulatory review in a large number
of countries globally, and in November 2012 the European Committee for Human
Medicinal Products issued a positive recommendation for approval of the product
in Europe.
Zealand Pharma has a partnering strategy for the development and
commercialization of its products and in addition to the collaboration with
Sanofi in Type 2 diabetes, the company has partnerships with Boehringer
Ingelheim in diabetes/obesity, Abbott in acute kidney injury and Helsinn
Healthcare in chemotherapy induced diarrhea. Zealand Pharma focuses its
activities in disease areas where existing treatments fail to adequately serve
patient needs and where the market potential for improved treatments through
the use of peptide drugs is high.
For further information:
www.zealandpharma.com
1. Lyxumia is the proprietary name submitted to the EMA for lixisenatide. The
proprietary name for lixisenatide in the United States is under consideration.
Lixisenatide is not currently approved or licensed anywhere in the world.